drugset / Trial / NCT03638128
Open-label Extension of Study 20130173 of Denosumab in Children and Young Adults With Osteogenesis Imperfecta
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To evaluate long-term safety of denosumab in children/young adults with pediatric osteogenesis imperfecta (OI) who completed the prior study 20130173 (NCT02352753).
Timeline
- Start
- 2018-07-26
- Primary completion
- 2022-03-28
- Completion
- 2022-03-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Denosumab | Monoclonal antibody | 1 mg/kg | Subcutaneous |